Nestle enters agreement to develop ulcerative colitis therapy

Reuters Health Information: Nestle enters agreement to develop ulcerative colitis therapy

Nestle enters agreement to develop ulcerative colitis therapy

Last Updated: 2015-09-16

By Reuters Staff

ZURICH (Reuters) - Nestle is working with Lipid Therapeutics to develop and commercialize a new therapeutic treatment for mild-to-moderate ulcerative colitis, the company said on Wednesday.

The LT-02 compound (phosphatidylcholine) under development by Nestle can help to heal ulcers and restore lining of the colon wall, reducing chances of the condition returning, the company said.

Phase III clinical trials in the US are scheduled to start in 2016.

"These trials will primarily assess LT-02 as an add-on therapy in patients with UC not adequately responding to standard doses of 5-aminosalicylic acid, the current standard treatment for the condition," Lipid Therapeutics said in a statement.

© Copyright 2013-2018 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.